A substantial level of mixed chimerism is required for the induction of permanent transplantation tolerance

Transplant Immunology

Volumn 4, Issue 3, 1996, Pages 232-240

  De Vries Van Der Zwan, Anneke ^a   Besseling, Arit C ^a   Van Twuyver, Esther ^a   Boog, Claire J P ^a,b   De Waal, Leo P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; MONOCLONAL ANTIBODY CD3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN ALLOGRAFT; T LYMPHOCYTE; TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 0030248758     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(96)80023-2     Document Type: Article

References (31)

1. 1 Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989; 169: 493-502.
2. 2 Qin S, Cobbold S, Benjamin R, Waldmann H. Induction of classical transplantation tolerance in the adult. J Exp Med 1989; 169: 779-94.
3. 3 Mayumi H, Good RA. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide. J Exp Med 1989; 169: 213-38.
4. 4 Hewitt CW, Ramsamooj R, Patel MP, Yazdi B, Achauer BM, Black KS. Development of stable mixed T cell chimerism and transplantation tolerance without immune modulation in recipients of vascularized bone marrow allografts. Transplantation 1990; 50: 766-72.
5. 5 Leong LYW, Qin S, Cobbold SP, Waldmann H. Classical transplantation tolerance in the adult: the interaction between myeloablation and immunosuppression. Eur J Immunol 1992; 22: 2825-30.
6. 6 Colson YL, Wren SM, Schuchert MJ et al. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J Immunol 1995; 155: 4179-88.
7. 7 De Vries-van der Zwan A, Besseling AC, Kievits F, van Twuyver E, de Waal LP. Anti-CD3 treatment facilitates engraftment of full H-2 disparate donor bone marrow cells and subsequent skin allograft tolerance. Transplantation 1994; 58: 610-17.
8. 8 Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 1987; 84: 1374-78.
9. 9 Ellenhorn JDI, Hirsch R, Schreiber H, Bluestone JA. In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science 1988; 242: 569-71.
10. 10 Hirsch R, Eckhaus M, Auchincloss Jr H, Sachs DH, Bluestone JA. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol 1988; 140: 3766-72.
11. 11 Hirsch R, Gress RE, Pluznik DH, Eckhaus M, Bluestone JA. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol 1989; 142: 737-43.
12. 12 Hiruma K, Hirsch R, Patchen M, Bluestone JA, Gress RE. Effects of anti-CD3 monoclonal antibody on engraftment of T-cell-depleted bone marrow allografts in mice: host T-cell suppression, growth factors, and space. Blood 1992; 79: 3050-58.
13. 13 Ferran C, Sheehan K, Dy M et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 1990; 20: 509-15.
14. 14 Sheng-Tanner X, Miller RG. Correlation between lymphocyte-induced donor-specific tolerance and donor cell recirculation. J Exp Med 1992; 176: 407-13.
15. 15 Van Twuyver E, Mooijaart RJD, ten Berge DM et al. Pretransplant blood transfusion revisited. N Engl J Med 1991; 325: 1210-13.
16. 16 Lagaaij EL, Ruigrok MB, van Rood JJ et al. Blood transfusion induced changes in cell-mediated lympholysis: to immunize or not to immunize. J Immunol 1991; 147: 3348-52.
17. 17 Pierce GE. Allogeneic versus semiallogeneic F1 bone marrow transplantation into sublethally irradiated MHC-disparate hosts. Transplantation 1990; 49: 138-44.
18. 18 Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168-70.
19. 19 Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Sachs DH. Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med 1985; 162: 231-44.
20. 20 Wren SM, Hronakes ML, Ildstad ST. The requirement for allogeneic chimerism for second transfer of tolerance from mixed allogeneic chimeras (A + B → A) to secondary recipients. Transplantation 1992; 54: 1031-40.
21. 21 Sharabi Y, Abraham VS, Sykes M, Sachs DH. Mixed allogeneic chimeras prepared by a non-myeloablative regimen: requirement for chimerism to maintain tolerance. Bone Marrow Transplant 1992; 9: 191-97.
22. 22 Kawai T, Cosimi AB, Colvin RB et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256-62.
23. 23 Jaques BC, Ahmidat H, Walker KG, Bolton EM, Bradley JA. Evidence that recent thymid emigrants play a critical role in anti-CD4 mAb induced transplant tolerance. In: Abstracts and proceedings of the 4th Basic Sciences Symposium of the Transplantation Society, 1995: 84-85.
24. 24 De Waal LP, van Twuyver E. Review: Blood transfusion and allograft survival: is mixed chimerism the solution for tolerance induction in clinical transplantation? Crit Rev Immunol 1991; 10: 417-25.
25. 25 Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. Lancet 1992; 339: 1579-82.
26. 26 Starzl TE, Demetris AJ, Trucco M et al. Systemic chimerism in human female recipients of male livers. Lancet 1992; 340: 876-77.
27. 27 Starzl TE, Demetris AJ, Trucco M et al. Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation 1993; 55: 1272-77.
28. 28 Collins R, Anastasi J, Terstappen L et al. Donor-derived long-term multilineage hematopoiesis in a liver-transplant recipient. N Engl J Med 1993; 328: 762-65.
29. 29 Fontes P, Rao AS, Demetris AJ et al. Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet 1994; 344: 151-55.
30. 30 Rao AS, Fontes P, Zeevi A et al. Augmentation of chimerism in whole organ recipients by simultaneous infusion of donor bone marrow cells. Transplant Proc 1995; 27: 210-12.
31. 31 Cirocco R, Garcia R, Karatzas T et al. Engraftment of donor cells in the peripheral blood of bone marrow infused solid organ recipients: increased levels of chimerism in liver versus kidney recipients. In: Abstracts and proceedings of the 4th Basic Sciences Symposium of the Transplantation Society, 1995: 405.